step 1 trial semaglutide 2.4 mg weight loss nejm 2021 Once-weekly 7·2 in adults with obesity (STEP UP): a randomised, controlled, phase 3b Semaglutide 2.4 mg for the
Description
Providers should also assess medication adherence and GI tolerance capacity, as dual therapy demands careful monitoring during initiation and titration phases

Comparative Receptor Mechanisms and Efficacy Expectations Tirzepatide activates both GIP and GLP-1 receptors, producing synergistic glucose control and robust weight loss averaging 20-22% at maximum dose in clinical trials

Share Link: How fast can I expect to lose weight
Use reliable contraception while on treatment

Ketosis: Ozempic can cause ketosis (a metabolic state where your body burns fat for energy instead of carbohydrates), which may cause a distinct breath odor
